Business Description
Vaxil Bio Ltd. is a Canadian biotechnology company developing new treatments for cancer and infectious diseases using a technology built around signal peptides. Their most advanced product, ImMucin, is a vaccine targeting a protein called MUC1 and has already been tested in an early-stage clinical trial for multiple myeloma, a type of blood cancer. The company operates out of Toronto, Canada.
